How accurate is serologic testing of plasma pools for hepatitis b virus surface antigen, anti-human immunodeficiency virus 1 and 2, and anti-hepatitis c virus?

Transfusion Medicine and Hemotherapy

Volumn 23, Issue 3, 1996, Pages 124-130

  Rabenau, H ^a   Schutz R ^b   Berger, A ^a   Doerr, H W ^a   Weber, B ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Octapharma   (Germany)

Author keywords

HBV; HCV; HIV; Immunoassay; Plasma pool

Indexed keywords

MEMBRANE ANTIGEN;

ARTICLE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; PLASMA;

AIDS SERODIAGNOSIS; ANTIGEN-ANTIBODY COMPLEX; BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CROSS-CULTURAL COMPARISON; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 0029681650     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000223281     Document Type: Article

References (26)

1. Dodd RY, Moroff G, Wagner S, Dabay MH, Dorf-man E, George V, Ribeiro A, Shumaker J, Benade LE: Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: Comparison of psoralen-ultraviolet A and merocyanine 540-visible light methods, Transfusion 1991;31:483-490.
2. Centers for Disease Control: Safety of therapeutic products used for hemophilia patients, J Am Med Assoc 1989:260:901-903.
3. Klein RS, Friedland GH: Transmission of human immunodeficiency virus type 1 (HIV-1) by exposure to blood: Defining the risk, Ann Intern Med 1990;113:729-730.
4. Normann A, Graft J, Gcrritzen A, Brackman HH, Flehmig B: Detection of hepatitis A virus RNA in commercially available factor VIII preparation, Lancet 1992;340:1232-1233.
5. Niibling CM, Willkommen H, Lower J: Hepatitis C transmission associated with intravenous immun-globulins, Lancet 1995;345:1174.
6. Qu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD, Biswas RM: Hepatitis C transmission associated with intravenous immunglobulins, Lancet 1995;345:1173-1174.
7. Kühnl P, Seidl S, Böhm BO: Reduction of virus load in blood donations by screening methods; in Morgenthaler JJ (ed): Virus Inactivation in Plasma Products: Curr Stud Hematol Blood Transfus, Basel, Karger, 1989, vol 56, pp 9-22.
8. Rabenau H: Die Virussicherheit von Blutprodukten: Aspekte der behördlichen Anforderungen, Lab Med 1995:19:523-533.
9. Burnouf T Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates, Bio-logicals 1992;20:91-100.
10. Wagner SJ, Friedman LI, Dodd RY: Approaches to the reduction of viral infcctivity in cellular blood components and single donor plasma, Transfus Med Rev 1991;5:18-32.
11. Edwards CA, Piet MPJ, Chin S, Horowitz B: Tri (n-butyl)phosphate/detergent treatment of licenced therapeutic and experimental blood derivates, Vox Sang 1987;52:53-59.
12. Roggendorf M: Bedeutung der HCV-Infektion für die posttransfusionellc Hepatitis, InfusionsthcrTrans-fusionsmed 1994;21 (Supplement 1): 12-18.
13. Ingerslev J: Safety of plasma derivates, Haemostasis 1994;24:311-323.
14. European Pharmacopoeia: Plasma humanum ad separationem, 2nd ed, Sainte-Ruffinc (Frankreich), Maisonneuve, 1995, p 853.
15. Sachs L: Angewandte Statistik, Berlin, Springer, 1992.
16. Pokriefka RA, Manzor O, Markowitz NP, Saravo-latz LD, Kvale P, Donovan RM; Increased detection of human immunodeficiency virus antigenemia after dissociation of immune complexes at low pH, J Clin Microbiol 1993;31:1656-1658.
17. Seagrott V, Magrath DI, Ferguson M, Anderson SG, Schild GC, Cameron CH: Preliminary evaluation of a collaborative study of the proposed British Standard for hepatitis B surface antigen, Med Lab Sei 1981;38:335-339.
18. Ramskill S: HBsAg standards (newsletter), Transfus Microbiol 1989;10:8-9.
19. Blum HE, Liang TJ, Galun E, Wands JR: Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection, Hepatology 1991;14:56-63.
20. Kuhns M, McNamara A, Mason A, Campbell C, Pcrillo R: Scrum and liver hepatitis B DNA in chronic hepatitis B after sustained loss of surface antigen, Gastroenterology 1992;103:1649-1656.
21. Michalck TI, Pasquinclli C, Guilhot S, Chisari FV: Hepatitis B virus persistence after recovery from acute hepatitis, J Clin Invest 1994;93:230-239.
22. Hollinger FB: Hepatitis B virus; in Fields B (ed): Virology, 2nd ed, New York, Raven Press, 1990.
23. Van der Poel CL, Reesin HW, Mauser-Bunschotcn EP, Kaufmann RII, Lcentvaar-Kuypers A, Chamu-leau R, Schaasberg W, Bakker E, Exel-Oohlers PJ, Theobalds I, Van Boven JP, Caneron A, Lelie PM: Prevalence of anti-HCV antibodies confirmed by recombinant immunoblot in different population subsets in the Netherlands, Vox Sang 1991;61:30-36.
24. Laufs R, Polywka S, Feucht HH, Ebeling M, Iske L, Friedrich K, Oehler G, Keitel M, Nolle H, Thiele A: Was bedeutet der Befund rHCV-Antikörper positive? Dtsch Ärztebl 1994;91:B238-B240.
25. Weber B: Neue virologische Aspekte der HCV-Infcktion; in Scharrer I, Schramm W (Hrsg): 25, Hämophilie-Symposium Hamburg 1994, Berlin, Springer, 198.
26. Weber B, Hess G, Koberstein R, Doerr HW: Evaluation of the automated Enzymun-test anti HIV-1+2 and Enzymun-test anti HI V-1/2 selective for the combined detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies, J Virol Methods 1993;44: 251-263.